Highlights Aditxt, Inc.

Equities

ADTX

US0070256047

Delayed Nasdaq Other stock markets 18:41:15 13/05/2024 BST			5-day change	1st Jan Change
2.06 ^USD	-0.48%		-4.63%	-68.93%

05-03	Aditxt, Inc. announced that it expects to receive $4.2 million in funding	CI
05-02	Aditxt, Inc. announced that it expects to receive $150 million in funding	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Aditxt, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-16	CI
Appili Therapeutics To be Acquired by Aditxt, Inc.	04-02	MT
Aditxt, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Aditxt, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
Aditxt, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
ADITXT, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	17/04/23	AQ
Aditxt, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	17/04/23	CI
Aditxt's Pearsanta Unit Selected as Backup Bidder to Acquire Lucira Health's Assets	17/04/23	MT
Aditxt Says Unit Pearsanta Submitted Bid to Acquire All of Lucira Health Assets	17/04/23	CI
Aditxt, Inc. Announces the Formation of A U.S. Based Wholly- Owned Subsidiary, Pearsanta, Inc	14/02/23	CI
Aditxt, Inc. Forms Adimune, Inc. as Subsidiary	03/01/23	CI
ADITXT, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	14/11/22	AQ
Aditxt, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22	CI
Aditxt, Inc. Announces Development and Publication of Mathematical Model for Predicting Longevity and Variations of Immune Response to Immunization to SARS-CoV-2 Infection	12/10/22	CI
Aditxt Regains Compliance With Nasdaq's Minimum Bid Price Rule	29/09/22	MT
Aditxt to Trade on 1-for-50 Reverse Stock Split Adjusted Basis From Sept. 14	13/09/22	MT
ADITXT, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	15/08/22	AQ
Aditxt, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	15/08/22	CI
Aditxt, Inc. Successfully Completes Preclinical Toxicity Study of Its Psoriasis Drug Candidate ADI™-100 Advancing it Closer to First-in-Human Trials	08/07/22	CI
Aditxt, Inc. cancelled the acquisition of AiPharma from AiPharma Global Holdings LLC.	14/06/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Aditxt, Inc.

Equities

ADTX

US0070256047

Highlights

Filters